Chang-Lu Hu

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Xinan Sheng, Lin Wang, Zhisong He et al. · Journal of Clinical Oncology · 2023 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pin Zhang, Qingyuan Zhang, Zhongsheng Tong et al. · The Lancet Oncology · 2023 · 95 citations

Medicine, Oncology, Pharmacology +16

Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

Xiao-Peng Tian, Wei-Juan Huang, Hui-Qiang Huang et al. · Leukemia · 2019 · 71 citations

Life Sciences, Cancer Biology, Oncology +16

LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis

Qi Chen, Huachao Xu, Jiang Zhu et al. · Biomedicine & Pharmacotherapy · 2020 · 70 citations · Full text

Life Sciences, Molecular Biology, Oncology +17